About Dipanjan Banchur
Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. His goal is to help investors make the best investment decisions based on a fundamental approach.
Recent Articles By Dipanjan Banchur
Motorola Solutions (MSI) Quarterly Earnings: What to Watch For
Chicago-based Motorola Solutions (MSI) will release its fourth-quarter and full-year results on February 8. Given the strong demand for its products and solutions, the company has bolstered its revenue and earnings estimates for fiscal 2023. Therefore, should investors consider buying the stock now? Read on to learn my view…
SPGI Quarterly Earnings Preview: Buy or Hold Decision?
S&P Global (SPGI) will release its fourth-quarter results on February 8. Analysts expect the company to report a year-over-year increase in revenue and earnings for the quarter. Moreover, the company is expected to finish fiscal 2023 on a solid note. Therefore, should investors consider buying the stock now? Read on to learn my view…
CVS Health (CVS) Pre-Earnings Analysis: Buy or Hold?
The largest U.S. drugstore chain, CVS Health (CVS), will release its fourth-quarter results on February 7. The company is expected to report year-over-year growth in revenue and earnings. With the expected rise in medical costs during the fourth quarter, should investors consider buying the stock now? Read on to learn my view…
Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?
Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn my view…
3 Lucrative Pharma Stocks for Portfolio Success
The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio. Keep reading...
3 Tech Wonders Unlocking Gains
Rising digitization spending and the adoption of cutting-edge technologies are driving the tech industry forward. Amid this backdrop, it could be wise to consider buying fundamentally strong tech stocks Garmin (GRMN), NetScout (NTCT), and Stratasys (SSYS). Read more…
Pharma Stock Analysis: Buy, Hold, or Sell These 4?
Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on...
Add These 3 Booming Tech Stocks to Your Portfolio Now
Growing digitization initiatives and the increasing reliance of companies on advanced technologies are fuelling the tech industry’s growth. Given these factors, it could be prudent to add fundamentally strong tech stocks Wipro (WIT), Proto Labs (PRLB), and Bel Fuse (BELFB) to one’s portfolio. Keep reading…
4 Auto Stock Buys With Explosive Profit Potential
The auto industry looks well-positioned for expansion, driven by pent-up demand for new cars, rapid EV adoption, rising disposable incomes, easing of global supply chains, and the use of advanced technologies in vehicles. Amid this backdrop, it could be wise to buy fundamentally strong auto stocks Mercedes-Benz (MBGAF), Mazda (MZDAY), Honda (HMC) and REVG (REVG) with substantial profit potential. Read on...